Accuray Incorporated — Form 10-K Summary
Period: Fiscal year ended June 30, 2014; filed August 29, 2014. The request metadata says “2013 Q4,” but the supplied filing is an annual report for FY2014. Accuray develops, sells and services CyberKnife radiosurgery and TomoTherapy radiation-therapy systems.
Financial performance
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $369.4 million | $316.0 million |
| Product revenue | $173.6 million | $137.4 million |
| Service revenue | $195.8 million | $178.6 million |
| Gross profit / margin | $142.8 million / 39% | $97.6 million / 31% |
| Operating loss | $18.1 million | $80.7 million |
| Net loss attributable to stockholders | $35.4 million | $103.2 million |
| Net loss per share, diluted | $0.47 | $1.41 |
| Operating cash flow | $0.3 million | $(66.2) million |
- Revenue increased 17% year over year. Product revenue rose 26%, with systems sold up 40%; service revenue increased 10%, reflecting a larger installed base and higher-priced maintenance contracts.
- Gross margin improved eight percentage points. Management cited higher volume and lower obsolete-inventory charges for product margin gains, and improved TomoTherapy reliability and service-contract mix for service margin gains.
- Operating expenses were $160.9 million, down 10%. R&D declined 19% to $53.7 million, while selling and marketing rose 14% to $61.9 million. G&A fell 21% to $45.3 million, partly because FY2013 included restructuring and severance costs.
- Cash from operations was only $0.3 million despite the narrower loss; capital expenditures were $11.9 million, implying approximately $11.6 million of negative operating-cash-flow less capital-expenditure cash generation.
Balance sheet, liquidity and debt
- At June 30, 2014, cash and cash equivalents were $92.3 million and short-term investments were $79.6 million, for $171.9 million combined. Working capital was $179.9 million; current assets were $364.5 million and current liabilities were $184.6 million.
- Long-term debt carrying value was $195.6 million; convertible-note principal totaled $215.0 million. Notes carry coupons of 3.5% or 3.75%, with maturities in 2016 and 2018. FY2014 interest expense was $14.3 million.
- In April 2014, Accuray exchanged approximately $70.3 million of 3.50% notes for Series A convertible notes of approximately the same principal, paying about $0.4 million in cash. The Series A notes have an initial conversion price of about $5.33 per share; conversion or settlement could affect liquidity and dilute shareholders.
- Management said existing cash, investments and anticipated cash flows should fund operations for at least 12 months. This is not a guarantee; operating cash flow was close to break-even and the company remains loss-making.
Changes, outlook and key developments
- Results improved substantially from FY2013, when revenue had fallen 23% and the company recorded a $103.2 million net loss. FY2014 revenue remained below FY2012’s $409.2 million.
- Product backlog was $364.7 million at year-end. It included $40.7 million of orders for CyberKnife M6 systems or upgrades configured with the multi-leaf collimator (MLC), whose field evaluation was ongoing, and $33.3 million of CyberKnife orders with technology-protection upgrade options. Backlog may not convert to revenue.
- Management expected FY2015 R&D expense to exceed FY2014 levels based on planned development work, and selling and marketing expense to increase due to anticipated headcount and compensation growth. No specific revenue or earnings guidance is provided in the supplied filing text.
- CyberKnife production was being shifted from Sunnyvale to Madison, with completion expected by the end of calendar 2014. The transition could cause disruption, extra costs or regulatory delays.
- The company reported an accumulated deficit of $355.1 million and stated that future profitability depends on sales growth, cost control and maintaining or improving margins. International markets generated 58% of FY2014 revenue.
Risks, contingencies and unusual items
- Key risks include reliance on major capital-equipment purchases and lengthy sales and installation cycles; customer financing delays or cancellations; uncertain reimbursement and regulatory approvals; strong competition; and dependence on single-source suppliers.
- The CyberKnife M6 MLC had supplier yield and durability problems, delaying its launch. Accuray said internal testing was satisfactory and field evaluation had begun, but further delays remained possible.
- Accuray initiated one CyberKnife recall or product correction in FY2014; it reported no serious adverse health consequences and said costs were not material. FDA inspections in 2012 recorded minor observations at Sunnyvale, classified initially as Voluntary Action Indicated; corrective action was underway. Madison had no observations.
- Legal matters included a pending patent suit by Sarif Biomedical, a distributor arbitration brought by former China distributor Cowealth, and an appeal in the Rotary Systems trade-secret case. Two Best Medical cases settled and were dismissed with prejudice in June 2014. Management estimated possible aggregate losses, beyond accrued amounts, of $0 to $0.5 million for certain proceedings where estimable.
- FY2013 included CPAC discontinued-operation losses, including a $12.2 million impairment and a $3.4 million deconsolidation loss; these did not recur in FY2014. FY2013 also included $9.1 million of restructuring charges.
- Accuray had $320.5 million of federal and $166.8 million of state net operating loss carryforwards, but maintained a full valuation allowance against domestic net deferred tax assets. The company said it intended to reinvest $14.7 million of undistributed foreign earnings overseas.
- The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Management also concluded disclosure controls and internal financial controls were effective as of June 30, 2014.
Investor verification priorities
- Verify whether the backlog—especially the MLC-related orders and upgrade options—converts into shipments, installations and recognized revenue.
- Track MLC field performance, CyberKnife production-transfer execution, and any related customer, quality or regulatory effects.
- Assess whether gross-margin improvement and revenue growth persist as planned FY2015 R&D and selling costs rise.
- Monitor operating cash flow, receivables, inventory, and cash available after capital spending, alongside the $215.0 million convertible-note principal and conversion terms.
- Review updates on reimbursement rates, international demand, supplier concentration, and the Sarif, Cowealth and Rotary Systems proceedings.